Stock ScreenerStock IdeasSmall Cap GrowthBest Small Cap Growth Stocks 2025Companies with small market capitalization and a 5 year track record of explosive revenue growth
Stock ScreenerStock IdeasSmall Cap Growth
Market Cap: $50M - $2B
Accelerating Revenue Growth: Pass
Revenue Growth vs Industry: Pass
Revenue Growth vs Market: Pass
| Ticker | Company | DD Score | Valuation Score | Financials Score | Forecast Score | Performance Score | Dividends Score |
|---|---|---|---|---|---|---|---|
| SPRY | ARS PHARMACEUTICALS INC | 60 | 14 | 86 | 89 | 50 | – |
| GERN | GERON CORP | 38 | 14 | 43 | 56 | 40 | – |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | 38 | 14 | 43 | 56 | 40 | – |
| PHAT | PHATHOM PHARMACEUTICALS INC | 27 | 14 | 29 | 33 | 30 | – |
| FULC | FULCRUM THERAPEUTICS INC | 47 | 14 | 100 | 22 | 50 | – |
Upgrade to Premium to View More
Use Due Diligence Score to quickly analyze stock fundamentals, even if you don't have a finance background. We run time-tested due diligence checks inspired by legendary investors like Warren Buffett, and score each company based on how many they pass/fail.
Already have a premium account? Sign In
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.